# OnCo record paper-prodige-24-adjuvant-mfolfirinox-pancreatic-nejm-2018 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-prodige-24-adjuvant-mfolfirinox-pancreatic-nejm-2018/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-prodige-24-adjuvant-mfolfirinox-pancreatic-nejm-2018" ;
  schema:name "PRODIGE 24/CCTG PA6: adjuvant modified FOLFIRINOX versus gemcitabine after resection of pancreatic cancer"@en ;
  schema:description "Six months of the four-drug combination modified FOLFIRINOX after surgery for pancreatic cancer kept the disease away for almost twice as long as gemcitabine alone and added about a year and a half to median survival. It is the reason fit patients are now offered FOLFIRINOX after a pancreatic operation."@en ;
  schema:url <https://onco.cc/key-papers/paper-prodige-24-adjuvant-mfolfirinox-pancreatic-nejm-2018/> ;
  schema:dateModified "2026-09-21"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa1809775>, <https://pubmed.ncbi.nlm.nih.gov/30575490/> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa1809775> ;
  schema:datePublished "2018"^^xsd:gYear ;
  schema:author "Conroy T, Hammel P, Hebbar M, et al." ;
  onco:cancers <https://onco.cc/cancers/resectable-pdac/>, <https://onco.cc/cancers/pancreatic/> ;
  onco:drugs <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/drugs/gemcitabine/> ;
  onco:trials <https://onco.cc/trials/prodige-24/> ;
  onco:people <https://onco.cc/people/thierry-conroy/> ;
  onco:journals <https://onco.cc/journals/nejm/> .